HUE064637T2 - Vegyületek glikogéntárolási betegségek kezelésére - Google Patents
Vegyületek glikogéntárolási betegségek kezeléséreInfo
- Publication number
- HUE064637T2 HUE064637T2 HUE18757731A HUE18757731A HUE064637T2 HU E064637 T2 HUE064637 T2 HU E064637T2 HU E18757731 A HUE18757731 A HU E18757731A HU E18757731 A HUE18757731 A HU E18757731A HU E064637 T2 HUE064637 T2 HU E064637T2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- treatment
- glycogen storage
- storage disorders
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000007345 glycogen storage disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461884P | 2017-02-22 | 2017-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE064637T2 true HUE064637T2 (hu) | 2024-04-28 |
Family
ID=63254263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18757731A HUE064637T2 (hu) | 2017-02-22 | 2018-02-22 | Vegyületek glikogéntárolási betegségek kezelésére |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11053231B2 (hu) |
| EP (2) | EP4292652A3 (hu) |
| ES (1) | ES2967218T3 (hu) |
| HU (1) | HUE064637T2 (hu) |
| IL (3) | IL290955B2 (hu) |
| PL (1) | PL3585786T3 (hu) |
| WO (1) | WO2018154578A1 (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (ko) * | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| US20230173037A1 (en) * | 2020-03-09 | 2023-06-08 | University Of Kentucky Research Foundation | Manipulating Glycogen in Alzheimer’s Disease, Epilepsy, Traumatic Brain Injury, and ALS as a Treatment |
| BR112023016482A2 (pt) * | 2021-02-16 | 2023-10-24 | Hadasit Med Res Service | Compostos estabelecidos como alvo de proteína de membrana associada ao lisossoma e usos dos mesmos |
| WO2024042523A1 (en) | 2022-08-24 | 2024-02-29 | Lyotropic Delivery Systems Ltd. | Oral delivery of active compounds for treating glycogen storage diseases |
| WO2024059661A1 (en) * | 2022-09-14 | 2024-03-21 | Maze Therapeutics, Inc. | N-(benzhydryl)cycloalkylcarboxamide derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2024059659A1 (en) * | 2022-09-14 | 2024-03-21 | Maze Therapeutics, Inc. | Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524870B2 (en) * | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
| WO2011035064A2 (en) * | 2009-09-16 | 2011-03-24 | University Of Tennessee Research Foundation | Triazole catalysts and methods of making and using the same |
| US7947728B1 (en) * | 2009-11-11 | 2011-05-24 | Hoffmann-La Roche Inc. | Indole and indazole analogs as glycogen synthase activators |
| US20110118314A1 (en) | 2009-11-16 | 2011-05-19 | Weiya Yun | Piperidine analogs as glycogen synthase activators |
| WO2016161086A1 (en) | 2015-03-31 | 2016-10-06 | Duke University | Methods and compositions for treating glycogen storage diseases using agents that mimic or elevate cyclic amp |
| US20180200324A1 (en) * | 2015-07-23 | 2018-07-19 | Hadasit Medical Research Services And Development Ltd. | Artificial peptides and use thereof for glycogen storage disorders |
-
2018
- 2018-02-22 ES ES18757731T patent/ES2967218T3/es active Active
- 2018-02-22 EP EP23205410.6A patent/EP4292652A3/en active Pending
- 2018-02-22 PL PL18757731.7T patent/PL3585786T3/pl unknown
- 2018-02-22 WO PCT/IL2018/050207 patent/WO2018154578A1/en unknown
- 2018-02-22 IL IL290955A patent/IL290955B2/en unknown
- 2018-02-22 IL IL297569A patent/IL297569A/en unknown
- 2018-02-22 EP EP18757731.7A patent/EP3585786B1/en active Active
- 2018-02-22 HU HUE18757731A patent/HUE064637T2/hu unknown
- 2018-02-22 US US16/485,577 patent/US11053231B2/en active Active
-
2019
- 2019-08-13 IL IL268693A patent/IL268693B/en unknown
-
2021
- 2021-05-31 US US17/334,905 patent/US11891381B2/en active Active
-
2022
- 2022-10-27 US US17/975,214 patent/US12065435B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2967218T3 (es) | 2024-04-29 |
| EP4292652A2 (en) | 2023-12-20 |
| IL290955B (en) | 2022-11-01 |
| WO2018154578A1 (en) | 2018-08-30 |
| PL3585786T3 (pl) | 2024-03-18 |
| US11891381B2 (en) | 2024-02-06 |
| IL268693B (en) | 2022-03-01 |
| IL268693A (en) | 2019-10-31 |
| EP3585786A1 (en) | 2020-01-01 |
| IL297569A (en) | 2022-12-01 |
| EP4292652A3 (en) | 2024-02-21 |
| US20230065065A1 (en) | 2023-03-02 |
| US20210395237A1 (en) | 2021-12-23 |
| US11053231B2 (en) | 2021-07-06 |
| EP3585786B1 (en) | 2023-10-25 |
| IL290955B2 (en) | 2023-03-01 |
| IL290955A (en) | 2022-04-01 |
| US12065435B2 (en) | 2024-08-20 |
| US20200017484A1 (en) | 2020-01-16 |
| EP3585786A4 (en) | 2020-08-12 |
| EP3585786C0 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| IL290955A (en) | Compounds for the treatment of glycogen storage diseases | |
| HK1256721A1 (zh) | 用於治療眼部病症的化合物和組合物 | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL280570A (en) | Mini-GDE for the treatment of glycogen storage disease III | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
| HK1258073A1 (zh) | 治療細胞質糖原貯積失調的方法和組合物 | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| PT3724173T (pt) | Compostos para o tratamento de distúrbios neuromusculares | |
| RS65014B1 (sr) | Bromheksin za lečenje bola | |
| GB201603886D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201603882D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201506228D0 (en) | Methods For The Treatment Of Cardivascular Disorders |